A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
25 03 2021
25 03 2021
Historique:
received:
26
06
2020
accepted:
29
09
2020
pubmed:
18
10
2020
medline:
24
8
2021
entrez:
17
10
2020
Statut:
ppublish
Résumé
This phase 1 study investigated the recommended phase 2 dose (RP2D) of inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, in pediatric patients with multiple relapsed/refractory (R/R) CD22+ acute lymphoblastic leukemia (ALL). Patients (age ≥1 year or <18 years) received 3 doses of InO (days 1, 8, and 15) per course. Dose escalation was based on dose-limiting toxicities (DLTs) during course 1. Dose level 1 (DL1) was 1.4 mg/m2 (0.6, 0.4, 0.4 mg/m2) and DL2 was 1.8 mg/m2 (0.8, 0.5, 0.5 mg/m2). Secondary end points included safety, antileukemic activity, and pharmacokinetics. Twenty-five patients (23 evaluable for DLTs) were enrolled. In course 1, the first cohort had 1 of 6 (DL1) and 2 of 5 (DL2) patients who experienced DLTs; subsequent review considered DL2 DLTs to be non-dose-limiting. Dose was de-escalated to DL1 while awaiting protocol amendment to re-evaluate DL2 in a second cohort, in which 0 of 6 (DL1) and 1 of 6 (DL2) patients had a DLT. Twenty-three patients experienced grade 3 to 4 adverse events; hepatic sinusoidal obstruction syndrome was reported in 2 patients after subsequent chemotherapy. Overall response rate after course 1 was 80% (95% confidence interval [CI], 59% to 93%) (20 of 25 patients; DL1: 75% [95% CI, 43% to 95%], DL2: 85% [95% CI, 55% to 98%]). Of the responders, 84% (95% CI, 60% to 97%) achieved minimal residual disease (MRD)-negative complete response, and 12-month overall survival was 40% (95% CI, 25% to 66%). Nine patients received hematopoietic stem cell transplantation or chimeric antigen receptor T cells after InO. InO median maximum concentrations were comparable to simulated adult concentrations. InO was well tolerated, demonstrating antileukemic activity in heavily pretreated children with CD22+ R/R ALL. RP2D was established as 1.8 mg/m2 per course, as in adults. This trial was registered at https://www.clinicaltrialsregister.eu as EUDRA-CT 2016-000227-71.
Identifiants
pubmed: 33067614
pii: S0006-4971(21)00665-0
doi: 10.1182/blood.2020007848
pmc: PMC7995290
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Inotuzumab Ozogamicin
P93RUU11P7
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1582-1590Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 by The American Society of Hematology.
Références
Blood. 2017 Jun 22;129(25):3322-3331
pubmed: 28408462
Pediatr Blood Cancer. 2015 Jul;62(7):1171-5
pubmed: 25732247
Blood Cancer J. 2020 Jul 24;10(7):77
pubmed: 32709851
J Clin Oncol. 2008 Jan 10;26(2):190-5
pubmed: 18182661
Int J Hematol. 2011 Aug;94(2):185-192
pubmed: 21800074
J Clin Oncol. 2016 Dec 20;34(36):4381-4389
pubmed: 27998223
J Clin Oncol. 2016 Aug 1;34(22):2591-601
pubmed: 27269950
Leukemia. 2010 Feb;24(2):265-84
pubmed: 20010625
Lancet. 2010 Dec 11;376(9757):2009-17
pubmed: 21131038
Ann Intern Med. 1993 Feb 15;118(4):255-67
pubmed: 8420443
Klin Padiatr. 2013 May;225 Suppl 1:S73-8
pubmed: 23700062
Cancer. 2018 Oct 15;124(20):4044-4055
pubmed: 30307611
Chirality. 2011 Sep;23(8):660-71
pubmed: 21800378
Cancer. 2019 Jul 15;125(14):2474-2487
pubmed: 30920645
J Pharm Sci. 2004 Nov;93(11):2645-68
pubmed: 15389672
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Leukemia. 2003 Feb;17(2):468-70
pubmed: 12592351
Leukemia. 2007 Apr;21(4):706-13
pubmed: 17287857
Br J Haematol. 2020 Jul;190(1):e53-e56
pubmed: 32424837
J Pharmacokinet Pharmacodyn. 2019 Jun;46(3):211-222
pubmed: 30859374
Pediatr Blood Cancer. 2015 Jun;62(6):964-9
pubmed: 25728039
Bone Marrow Transplant. 2019 Nov;54(11):1868-1880
pubmed: 31092900
Blood. 2017 Jan 19;129(3):347-357
pubmed: 27903527
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
N Engl J Med. 2015 Oct 15;373(16):1541-52
pubmed: 26465987
Pediatr Blood Cancer. 2018 Oct;65(10):e27269
pubmed: 29873895
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Am J Hematol. 2018 Nov;93(11):E352-E355
pubmed: 30058145
Pediatr Blood Cancer. 2014 Feb;61(2):369-72
pubmed: 24000241
Leukemia. 2019 Apr;33(4):884-892
pubmed: 30267011
J Clin Oncol. 2008 Aug 1;26(22):3756-62
pubmed: 18669463
Leukemia. 2012 Feb;26(2):255-64
pubmed: 21869836
Clin Pharmacokinet. 2010 Oct;49(10):633-59
pubmed: 20818831